SuperworthC4 Therapeutics price to sales ratio CCCC
Market value divided by revenue over the last twelve months, since 2023.
- Today, Oct 23, 2026
- 10.7×
- 3-year median
- 7.9×
- Against its 3-year history
- 62nd
- percentile: 0 is its lowest day, 100 its highest
- 3-year range
- 2.2× to 36.4×
- Peer median
- 3.6×
C4 Therapeutics' price to sales ratio is 10.7× as of Oct 23, 2026.
That is above its 3-year median of 7.9×, close to the middle of its last 3 years.
Over that time it ranged from 2.2× in May 2025 to 36.4× in Mar 2024.
The median for 4 biotech stocks of a similar size is 3.6×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 10.7× | 5.9× | 14.9× |
| 2025 | 6.8× | 2.2× | 8.7× |
| 2024 | 7.9× | 7.9× | 36.4× |
| 2023 | 13.7× | 3.1× | 13.7× |
Against its peers
Companies in Biotechnology nearest C4 Therapeutics' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| CCCCC4 Therapeutics | 10.7× |
| PLXProtalix BioTherapeutics | 2.5× |
| MGTXMeiraGTx | 2.2× |
| VCELVericel | 7.1× |
| ADMAAdma Biologics | 4.7× |
| Peer median | 3.6× |
Where C4 Therapeutics ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on C4 Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.